Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib in Non-active Secondary Progressive Multiple Sclerosis
NCT07299019Phase 3Recruiting
- Sponsor
- Zenas BioPharma
- Start
- Mar 2026
- Primary completion
- Jun 2030
- Countries
- 20
01
Overview
A Phase 3 trial of orelabrutinib in secondary-progressive multiple sclerosis (SPMS), sponsored by Zenas BioPharma. Started Mar 2026; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT07299019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07299019.